Ernexa Therapeutics Inc. (ERNA)
Data as of , from SEC Form 4 filings.
See up to 3 months of ERNA. The 7-day demo opens the 1M and 3M ranges and puts ERNA on your watchlist.
Start 7-day demoLatest ERNA insider trades
About Ernexa Therapeutics Inc. (ERNA)
Ernexa Therapeutics Inc. files with the SEC under CIK 0000748592 and is classified as pharmaceutical preparations. It is grouped with Health Care companies on this site. A registration statement was filed on 3 February 2026. No offering has priced.
ERNA Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 8 | 160,247 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
ERNA insider transactions (Form 4)
299 Form 4 filings on record, the earliest from Nov 5, 2024, newest first.
| Traded | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| James Arthur Bristol - Director | Grant or award | Stock Option (Right to buy) | 8,320 | $0.00 | - | |
| James Arthur Bristol - Director | Grant or award | Stock Option (Right to buy) | 5,083 | $0.00 | - | |
| Peter Cicala - Director | Grant or award | Stock Option (Right to buy) | 5,943 | $0.00 | - | |
| Peter Cicala - Director | Grant or award | Stock Option (Right to buy) | 5,083 | $0.00 | - | |
| David Polinsky - Director | Grant or award | Stock Option (Right to buy) | 5,083 | $0.00 footnote F1 | - | |
| ||||||
| William A. Wexler - Director | Grant or award | Stock Option (Right to buy) | 5,943 | $0.00 | - | |
| Elena Ratner - Director | Grant or award | Stock Option (Right to buy) | 5,944 | $0.00 | - | |
| Sanjeev Luther - Officer | Grant or award | Stock Option (right to buy) | 118,848 | $0.00 | - | |
| Charles Cherington - 10% Owner | Open-market purchase | Common Stock | 4,000,000 | $0.50 footnote F2 | $2.00M | |
| Charles Cherington - 10% Owner | Open-market purchase | Warrants to Purchase Common Stock | 4,000,000 | - footnote F2 | - | |
| ||||||
| Sandra M. Gurrola - Officer | Option exercise | Common Stock | 30 | - | - | |
| Sandra M. Gurrola - Officer | Option exercise | Restricted Stock Units | 30 | $0.00 | - | |
| Charles Cherington - 10% Owner | Open-market purchase | Common Stock | 261,756 | - | - | |
| Charles Cherington - 10% Owner | Open-market purchase | Common Stock | 4,768,783 | - | - | |
| Charles Cherington - 10% Owner | Open-market purchase | Common Stock | 1,237,762 | - | - | |
| Charles Cherington - 10% Owner | Open-market purchase | Common Stock | 5,420,823 | - | - | |
| Charles Cherington - 10% Owner | Open-market purchase | Common Stock | 1,562,988 | - | - | |
| Charles Cherington - 10% Owner | Other | Common Stock | 2,819,546 | $187.50 | $1.41M | |
| Charles Cherington - 10% Owner | Open-market purchase | 6.0% Senior Convertible Promissory Notes due 2028 | 0 | - | - | |
| Charles Cherington - 10% Owner | Open-market purchase | Warrants (right to buy) | 83,916 | - | - | |
| Charles Cherington - 10% Owner | Open-market purchase | 6.0% Senior Convertible Promissory Notes due 2028 | 0 | - | - | |
| Charles Cherington - 10% Owner | Open-market purchase | Warrants (right to buy) | 83,916 | - | - | |
| Charles Cherington - 10% Owner | Open-market purchase | 12.0% Senior Convertible Notes due September 24, 2025 | 0 | $513,234,750.00 | - | |
| Charles Cherington - 10% Owner | Other | 12.0% Senior Convertible Notes due September 24, 2025 | 0 | $0.00 | - | |
| Charles Cherington - 10% Owner | Open-market sale | 12.0% Senior Convertible Notes due December 12, 2028 | 0 | - | - | |
| Charles Cherington - 10% Owner | Open-market sale | 6.0% Senior Convertible Promissory Notes due 2028 | 0 | - | - | |
| Charles Cherington - 10% Owner | Open-market sale | Warrants (right to buy) | 523,512 | - | - | |
| Charles Cherington - 10% Owner | Open-market sale | Warrants (right to buy) | 2,475,524 | - | - | |
| Charles Cherington - 10% Owner | Open-market sale | Warrants (right to buy) | 3,125,976 | - | - | |
ERNA insider trading FAQ
What is the latest insider trade for ERNA?
Ernexa Therapeutics Inc. (ERNA) had 6 insider filings in the last 90 days, with the most recent on 2 September 2026. The full record for ERNA runs to 9 Form 4 filings, the earliest from 5 November 2024. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying ERNA stock?
No insider purchases of ERNA were filed in the last 90 days. 12 purchases are on record for this company.
How many insiders are selling ERNA stock?
No insider sales of ERNA were filed in the last 90 days. 5 sales are on record for this company.
Where can I see ERNA SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects ERNA Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
9The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - James Arthur Bristol view on EDGAR
- - Peter Cicala view on EDGAR
- - David Polinsky view on EDGAR
- - William A. Wexler view on EDGAR
- - Elena Ratner view on EDGAR
- - Sanjeev Luther view on EDGAR
- - Charles Cherington view on EDGAR
- - Sandra M. Gurrola view on EDGAR
- - Charles Cherington view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where ERNA's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow ERNA with a 7-day demo
- ERNA on your watchlist
- Every ERNA Form 4 filing on record
- Up to 3 months of ERNA price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
